28 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
believe the benefits described above are necessary and appropriate to provide a competitive compensation package to our Named Executive Officers.
Table
6-K
EX-99.2
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
of uterine fibroids. The NDA submission includes the positive PRIMROSE 1 and PRIMROSE 2 full data package including week 52 data and post treatment follow-up
424B7
0zn1cmewj4
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
19e3 431merwxh
17 Feb 22
Shelf registration (foreign)
4:14pm
424B7
tjuqzp60h3tcydgglo3c
23 Nov 21
Prospectus with selling stockholder info
4:06pm
F-3
grekhx8
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
kjtoqpvu1eas6 g5qoge
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
xrx2tn3rhxt9qhmx1r
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.2
v9opy0b 4rpbw8
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.2
ul0 uiz3046vo08j1z
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
fcmu38
31 Mar 21
Current report (foreign)
7:15am
6-K
EX-99.2
atd7i8 2fbty
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-1.1
gwn2nn7d70l6jrk d2
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am